10x Genomics, Inc. (BMV:TXG)
Mexico · Delayed Price · Currency is MXN | Market Cap | 104.25B +272.6% |
| Revenue (ttm) | 11.52B +2.3% |
| Net Income | -408.43M |
| EPS | -3.24 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6 |
| Open | 335.54 |
| Previous Close | 332.00 |
| Day's Range | 335.54 - 335.54 |
| 52-Week Range | 150.00 - 363.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About 10x Genomics
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium p... [Read more]
Financial Performance
In 2025, 10x Genomics's revenue was $642.82 million, an increase of 5.25% compared to the previous year's $610.79 million. Losses were -$43.54 million, -76.16% less than in 2024.
Financial numbers in USD Financial StatementsNews
10x Genomics price target raised to $40 from $23 at Leerink
Leerink raised the firm’s price target on 10x Genomics (TXG) to $40 from $23 and keeps a Market Perform rating on the shares. The firm cites higher industry multiples. Key…
10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026
PLEASANTON, Calif., July 15, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will rep...
10x Genomics price target raised to $47 from $25 at TD Cowen
TD Cowen raised the firm’s price target on 10x Genomics (TXG) to $47 from $25 and keeps a Hold rating on the shares. The firm adjusted targets in the tools…
10x Genomics price target raised to $50 from $32 at Canaccord
Canaccord analyst Kyle Mikson raised the firm’s price target on 10x Genomics (TXG) to $50 from $32 and keeps a Buy rating on the shares. The firm updated its model…
10x Genomics price target raised to $37 from $22 at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh raised the firm’s price target on 10x Genomics (TXG) to $37 from $22 and keeps an Equal Weight rating on the shares. The firm is…
10x Genomics Transcript: Transcript
10x Genomics price target raised to $45 from $24 at Citi
Citi raised the firm’s price target on 10x Genomics (TXG) to $45 from $24 and keeps a Neutral rating on the shares.
10x Genomics price target raised to $40 from $30 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on 10x Genomics (TXG) to $40 from $30 and keeps an Overweight rating on the shares. The firm adjusted targets in…
Torex Gold Announces Results of Its 2026 Meeting of Shareholders
Meeting marks formal transition of Andrew Snowden into role of President and CEO Toronto, Ontario--(Newsfile Corp. - June 17, 2026) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) (O...
10x Genomics announces research collaboration with Cleveland Clinic
10x Genomics (TXG) announced a research collaboration with Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical care with research and education, to advance re...
10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer
Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms PLEASANTON, Calif., June 17, 2026 /PRNewswire/ --...
10x Genomics acquires Proteintech Genomics
10x Genomics (TXG) acquired Proteintech Genomics, a division within Proteintech Group, a company specializing in developing high-plex proteomic solutions for single cell and spatial applications on 10...
10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group
Acquisition Expands 10x Genomics' Capabilities in Proteomics PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerati...
10x Genomics Transcript: Bank of America Global Healthcare Conference 2026
Strong double-digit growth in single-cell and spatial consumables was reported, with the Atera platform launch marking a major milestone. Atera addresses key market bottlenecks, driving high initial demand and expected to consolidate the spatial portfolio over time. Future plans include automation, multi-omics, and expansion into clinical diagnostics.
10x Genomics price target raised to $22 from $20 at Morgan Stanley
Morgan Stanley raised the firm’s price target on 10x Genomics (TXG) to $22 from $20 and keeps an Equal Weight rating on the shares.
10x Genomics price target raised to $20 from $17 at JPMorgan
JPMorgan raised the firm’s price target on 10x Genomics (TXG) to $20 from $17 and keeps a Neutral rating on the shares.
10x Genomics price target raised to $23 from $17 at Deutsche Bank
Deutsche Bank raised the firm’s price target on 10x Genomics (TXG) to $23 from $17 and keeps a Hold rating on the shares.
10x Genomics reports Q1 EPS (10c), consensus (6c)
Reports Q1 revenue $150.8M, consensus $146.56M. “We had a solid start to the year, with double-digit growth in Single Cell consumables reaction volumes and double-digit growth in Spatial consumables r...
10x Genomics backs FY26 revenue view $600M-$625M, consensus $612.74M
16:15 EDT 10x Genomics (TXG) backs FY26 revenue view $600M-$625M, consensus $612.74M
10x Genomics Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 9% year-over-year (excluding settlement revenue), driven by strong consumables growth and the launch of Atera, which received robust pre-order demand. Guidance anticipates flat to modest full-year growth, with Atera shipments expected to drive Q4 revenue.
10x Genomics Earnings release: Q1 2026
10x Genomics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
10x Genomics Quarterly report: Q1 2026
10x Genomics has published its Q1 2026 quarterly earnings report on May 7, 2026.
10x Genomics Reports First Quarter 2026 Financial Results
PLEASANTON, Calif., May 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 20...
10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference
PLEASANTON, Calif., April 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate i...
10x Genomics Proxy statement: Proxy filing
10x Genomics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.